An overview on age related macular degeneration and recent advances in its management
Age-related macular degeneration (AMD) is a condition characterized, in the early stages, by slow development and progression, absence of symptoms over a number of years, and extensive retinal deposits called drusen, often associated with pigmentary abnormalities (early AMD).There is strong and c...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Phytochemistry & Organic Synthesis Laboratory
2014-03-01
|
| Series: | PhytoChem & BioSub Journal |
| Subjects: | |
| Online Access: | https://drive.google.com/file/d/0B8ZU6DpsSi6URGNIX1dmRFVTXzQ/view?usp=sharing |
| Summary: | Age-related macular degeneration (AMD) is a condition characterized, in the early stages, by slow
development and progression, absence of symptoms over a number of years, and extensive retinal deposits called
drusen, often associated with pigmentary abnormalities (early AMD).There is strong and consistent evidence that
increasing age, family history, obesity/high body mass index, and cataract surgery are associated with late AMD.
Smoking is the strongest and most consistently found modifiable risk factor for late AMD.Age-related macular
degeneration remains one of the most severe and profound disabilities encountered in medicine, particularly due to
the loss of the central vision and the high economic burden it places on patients and societies.Recent advances in
management of AMD is anti-angiogenic drugs. The identification of the crucial role played by vascular endothelial
growth factor (VEGF) in the pathogenesis of wet AMD hasallowed the development of VEGF-blocking agents such
as bevacizumab, pegaptanib and ranibizumab.
|
|---|---|
| ISSN: | 2170-1768 2170-1768 |